Immunotherapy: is a type of cancer treatment the helps the immune system to fight cancer. The immune system helps your body fight infections and other diseases. It uses substances made by the body or in a laboratory in order to improve or restore the body's immune system function.
DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
Over the last decade the cancer research field has seen a number of advances aimed at increasing the efficacy of treatments, reducing toxic side effects, and decreasing attrition rates of dr...
B7-H3 is actively being explored as an immunotherapy target for pediatric patients with solid tumors using monoclonal antibodies or T cells expressing chimeric antigen receptors (CARs). B7-H...
Immune escape mechanisms such as the induction/recruitment of immunosuppressive cells and the increased expression of various immunosuppressive molecules including PD-1/PD-1 ligands are esse...
DATE: July 07, 2020 TIME: 9:00 am PDT The widely used TNM staging system is poorly predictive of response to adjuvant chemotherapy in Stage II and III colon cancer. As a result, there is ove...
Brain malignancies can either originate from within the CNS (gliomas) or invade from other locations in the body (metastases). A highly immunosuppressive tumor microenvironment (TME) influen...
DATE: June 30, 2020 TIME: 9:00am PDT, 12:00pm EDT QC laboratories perform a critical role in demonstrating pharmaceutical products are consistently manufactured, safe, potent, and pure. At t...
DATE: June 18, 2020 TIME: 9:00am PDT, 12:00pm EDT Despite the success of immunotherapy against several malignancies including melanoma and lung adenocarcinoma, glioblastoma remains the excep...
The RNAscope in situ hybridization technology allows high sensitivity, specificity and spatial resolution providing pivotal single-cell gene expression information to gain better insights in...
Multiplex immunofluorescence IHC is a powerful technique to address the increasing research needs in immuno-oncology to better understand the tumor microenvironment. In this webinar, we will...
Neoantigen based personalized immuno-oncology drugs are a relatively new therapeutic avenue that have shown strong anti-tumor efficacy in the clinic. Neoantigen peptides have been widely rep...
While providing indispensable insight into immune processes, the live cell imaging of immune cells poses unique challenges due to their non-adherent nature. Suspension cells such as immune c...
Gene manipulation studies in primary human immune cells can answer important biological questions within a clinically relevant cellular context. In this webinar we explore the use of several...
Multiplexed immunofluorescent imaging sheds new light on cancer and other complex conditions. This imaging technique offers a deeper understanding of cells and their surroundings by providin...
A key step in the clinical production of CAR T cells is the expansion of engineered T cells. To generate enough cells for viable adoptive cell therapy, cells must be robustly stimulated, whi...
Immune checkpoint blockade has revolutionized the treatment for patients with cancer. Great efforts remain to better understand resistant mechanisms to treatment as well as means to improve...
Cancer cells can acquire immune resistance resulting in a loss of immunosurveillance. Tumor cells can upregulate PDL-1 which binds to PD-1. This complex inhibits CD8 Tumor Infiltrating cells...
Cancer initiation and virulence depends on mechanisms to evade host immunosurveillance and suppression of early invasion and growth. Distinct phenotypes of the immune infiltrates in and arou...
Dr. Koenitzer will present an overview of her current research in immune suppression. After a brief introduction to the MILLIPLEX® multiplex immunoassay portfolio, Dr. Koenitzer will dis...
Immune checkpoint therapies targeting the CTLA-4 and PD-(L)1 pathways have been largely clinically disappointing for patients with prostate cancer. This can be attributed to the highly immun...
Programmed death-1 (PD-1) inhibits T and B cell function upon ligand binding. PD-1 blockade revolutionized cancer treatment, and while numerous patients respond, some develop autoimmune-like...
1. Identify 3 barriers to immune cell response to cancer 2. List 3 approaches to overcome immunosuppressive barriers to bolster the immune response to cancer 3. Explain how fusion proteins c...
Platinum-based chemotherapy has been the cornerstone for treating metastatic urothelial cancer, which compromises the majority of bladder cancer. While urothelial cancer is chemosensitive, p...
DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
Over the last decade the cancer research field has seen a number of advances aimed at increasing the efficacy of treatments, reducing toxic side effects, and decreasing attrition rates of dr...
B7-H3 is actively being explored as an immunotherapy target for pediatric patients with solid tumors using monoclonal antibodies or T cells expressing chimeric antigen receptors (CARs). B7-H...
Immune escape mechanisms such as the induction/recruitment of immunosuppressive cells and the increased expression of various immunosuppressive molecules including PD-1/PD-1 ligands are esse...
DATE: July 07, 2020 TIME: 9:00 am PDT The widely used TNM staging system is poorly predictive of response to adjuvant chemotherapy in Stage II and III colon cancer. As a result, there is ove...
Brain malignancies can either originate from within the CNS (gliomas) or invade from other locations in the body (metastases). A highly immunosuppressive tumor microenvironment (TME) influen...
DATE: June 30, 2020 TIME: 9:00am PDT, 12:00pm EDT QC laboratories perform a critical role in demonstrating pharmaceutical products are consistently manufactured, safe, potent, and pure. At t...
DATE: June 18, 2020 TIME: 9:00am PDT, 12:00pm EDT Despite the success of immunotherapy against several malignancies including melanoma and lung adenocarcinoma, glioblastoma remains the excep...
The RNAscope in situ hybridization technology allows high sensitivity, specificity and spatial resolution providing pivotal single-cell gene expression information to gain better insights in...
Multiplex immunofluorescence IHC is a powerful technique to address the increasing research needs in immuno-oncology to better understand the tumor microenvironment. In this webinar, we will...
Neoantigen based personalized immuno-oncology drugs are a relatively new therapeutic avenue that have shown strong anti-tumor efficacy in the clinic. Neoantigen peptides have been widely rep...
While providing indispensable insight into immune processes, the live cell imaging of immune cells poses unique challenges due to their non-adherent nature. Suspension cells such as immune c...
Gene manipulation studies in primary human immune cells can answer important biological questions within a clinically relevant cellular context. In this webinar we explore the use of several...
Multiplexed immunofluorescent imaging sheds new light on cancer and other complex conditions. This imaging technique offers a deeper understanding of cells and their surroundings by providin...
A key step in the clinical production of CAR T cells is the expansion of engineered T cells. To generate enough cells for viable adoptive cell therapy, cells must be robustly stimulated, whi...
Immune checkpoint blockade has revolutionized the treatment for patients with cancer. Great efforts remain to better understand resistant mechanisms to treatment as well as means to improve...
Cancer cells can acquire immune resistance resulting in a loss of immunosurveillance. Tumor cells can upregulate PDL-1 which binds to PD-1. This complex inhibits CD8 Tumor Infiltrating cells...
Cancer initiation and virulence depends on mechanisms to evade host immunosurveillance and suppression of early invasion and growth. Distinct phenotypes of the immune infiltrates in and arou...
Dr. Koenitzer will present an overview of her current research in immune suppression. After a brief introduction to the MILLIPLEX® multiplex immunoassay portfolio, Dr. Koenitzer will dis...
Immune checkpoint therapies targeting the CTLA-4 and PD-(L)1 pathways have been largely clinically disappointing for patients with prostate cancer. This can be attributed to the highly immun...
Programmed death-1 (PD-1) inhibits T and B cell function upon ligand binding. PD-1 blockade revolutionized cancer treatment, and while numerous patients respond, some develop autoimmune-like...
1. Identify 3 barriers to immune cell response to cancer 2. List 3 approaches to overcome immunosuppressive barriers to bolster the immune response to cancer 3. Explain how fusion proteins c...
Platinum-based chemotherapy has been the cornerstone for treating metastatic urothelial cancer, which compromises the majority of bladder cancer. While urothelial cancer is chemosensitive, p...
Follow
